Published in AIDS Weekly, June 10th, 1996
"These preliminary data provide clear evidence of an antiviral effect in patients with recurrent genital herpes," said Dr. Stephen L. Sacks, Viridae Clinical Sciences, Vancouver, British Columbia. "These are very promising results that warrant further study."
Based on the data, Gilead said it has planned to move ahead with Phase II/II studies of cidofovir for the treatment of recurrent genital...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.